Testing VT-101 for non-muscle invasive bladder cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new drug called VT-101 for people with a type of bladder cancer that hasn't spread into the muscle wall. The goal is to see if the drug is safe and effective. It might be an option if you have already had a biopsy and are not eligible for or refuse surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a specific type of bladder cancer (non-muscle invasive) that is moderate to very high risk, confirmed by a biopsy within the last 8 weeks.
- You are in fairly good health (able to do most daily activities) and your doctor expects you to live at least 2 more years.
- Your blood tests show adequate organ function (kidneys, liver, bone marrow) within certain ranges.
- You agree to use effective birth control during the study and for 6 months after the last treatment (if you or your partner can become pregnant).
- You have not had certain other treatments recently, like surgery, radiation, or strong chemotherapy, except for a single bladder wash right after a biopsy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, 2141-V11, for people with bladder cancer that has not gone away after standard treatments like BCG therapy. It may help those with non-muscle invasive bladder cancer or, in one group, muscle-invasive bladder cancer, who cannot have or choose not to have bladder removal surgery.
This trial tests a new treatment called NDV01 KIT for people with high-grade non-muscle invasive bladder cancer that hasn't gotten better after BCG therapy. It's for those who cannot or choose not to have their bladder removed.
This trial tests an “oncolytic virus” treatment given into the bladder to fight high-grade non–muscle-invasive bladder cancer. It may help people whose bladder cancer did not respond to initial bladder prevention treatments, potentially delaying or avoiding major bladder surgery.
This trial tests STM-416, given around the time you have surgery to remove recurring bladder tumors, to see if it can reduce the chance the cancer comes back. It is for people with high-risk early bladder cancer (non–muscle-invasive) who have already had standard treatment and now need another TURBT.
This Phase 2 trial tests TARA-002 given directly into the bladder to treat high-grade non–muscle-invasive bladder cancer with active disease. It may help patients who have not previously responded to, or have not received, BCG treatment in the recent past.
This trial tests a new type of virus therapy that is put directly into the bladder for people with high-risk bladder cancer that hasn't spread into the muscle. The goal is to see if it is safe and effective at keeping the cancer from coming back.
Hear when a new Non Muscle Invasive Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.